For individuals now having medicines from an organization that was not next CGMP, FDA generally advises these consumers not to interrupt their drug therapy, which could have serious implications for their wellbeing. Shoppers should seek out advice from their overall health treatment specialists ahead of stopping or shifting drugs. Regulatory action